What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital”In the company’s words, NCT07024407 on ClinicalTrials.gov
- Main trialPhase 2/3
- “This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO) * Whether andecaliximab reduces the number or severity of flare-ups * Pharmacokinetics/pharmacodynamics (PK/PD): How…”In the company’s words, NCT06508021 on ClinicalTrials.gov
Other drugs for Fibrodysplasia Ossificans Progressiva
- GaretosmabRegeneron · Phase 3
- INCB000928Incyte Corporation · Phase 2
Coming up2
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 4 Feb 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 4 Feb 2029 | A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | |
| Phase 1/2Active, not recruiting | Dec 2028 | A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026